Acquired resistance to 6-thioguanine in melanoma cells involves the repair enzyme O6-methylguanine-DNA methyltransferase (MGMT)

Cancer Biology and Therapy

Volumn 9, Issue 1, 2010, Pages 49-55

  Gefen, Nir ^a   Brkic, Gordana ^a   Galron, Dalia ^b   Priel, Esther ^a   Ozer, Janet ^a   Benharroch, Daniel ^b   Gopas, Jacob ^a,b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

6 thioguanine; Drug resistance; Melanoma

Indexed keywords

GUANINE DERIVATIVE; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; O 6 BENZYLGUANINE; TIOGUANINE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DRUG DERIVATIVE; GUANINE; O (6) METHYLGUANINE; O-(6)-METHYLGUANINE;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DNA METHYLATION; DRUG SENSITIZATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; PHENOTYPE; PROTEIN EXPRESSION; UPREGULATION; DOSE RESPONSE; GENETICS; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GUANINE; HUMANS; MELANOMA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; THIOGUANINE;

EID: 75749144627     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.1.10285     Document Type: Article

References (40)

1. Elion GB. The purine path to chemotherapy. Science 1989; 244:41-7.
2. Coulthard S, Hogarth L. The thiopurines: an update. Invest New Drugs 2005; 23:523-32.
3. van Diggelen OP, Donahue TF, Shin SI. Basis for differential cellular sensitivity to 8-azaguanine and 6-thioguanine. J Cell Physiol 1979; 98:59-71.
4. Karran P. Thiopurines, DNA damage, DNA repair and therapy-related cancer. Br Med Bull 2006; 790:153-70.
5. Warren DJ, Andersen A, Slordal L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res 1995; 55:1670-4.
6. Pan BF, Nelson JA. Characterization of the DNA damage in 6-thioguanine-treated cells. Biochem Pharmacol 1990; 40:1063-9.
7. Parrish JA. Immunosuppression, skin cancer and ultraviolet A radiation. N Engl J Med 2005; 353:2712-3.
8. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005; 309:1871-4.
9. Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 1996; 273:1109-11.
10. Meyers M, Hwang A, Wagner MW, Boothman DA. Role of DNA mismatch repair in apoptotic responses to therapeutic agents. Environ Mol Mutagen 2004; 44:249-64.
11. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4:1-6.
12. Liu L, Gerson SL. Targeted modulation of MGMT: clinical implications. Clin Cancer Res 2006; 12:328-31.
13. 6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1- nitrosourea. Proc Natl Acad Sci USA 1985; 82:2985-9.
14. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4:296-307.
15. 6-methylguanine-DNA methyltransferase mRNA in rat hepatoma cells. Biochim Biophys Acta 1992; 1171:35-40.
16. 6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 1999; 18:525-32.
17. Daponte A, Ascierto PA, Gravina A, Melucci MT, Palmieri G, Comella P, et al. Cisplatin, dacarbazine and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group. Cancer 2000; 89:2630-6.
18. Passagne I, Evrard A, Depeille P, Cuq P, Cupissol D, Vian L. O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol 2006; 211:97-105.
19. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res 2000; 462:83-100.
20. Tanic N, Brkic G, Dimitrijevic B, Dedovic-Tanic N, Gefen N, Benharroch D, et al. Identification of differentially expressed mRNA transcripts in drug-resistant versus parental human melanoma cell lines. Anticancer Res 2006; 26:2137-42.
21. Brkic G, Gopas J, Tanic N, Dedovic-Tanic N, Benharroch D, Finkelstein-Jaworowsky E, et al. Genomic instability in drug-resistant human melanoma cell lines detected by Alu-I-arbitrary-primed PCR. Anticancer Res 2003; 23:2601-8.
22. 6-benzylguanine: a clinical trial establishing the biochemical modulatory dose in tumor tissue for alkyltransferase-directed DNA repair. Cancer Res 1999; 59:2402-10.
23. 6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 1994; 269:17228-37.
24. 6-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003; 24:625-35.
25. Karran P, Offman J, Bignami M. Human mismatch repair, drug-induced DNA damage, and secondary cancer. Biochimie 2003; 85:1149-60.
26. 6-alkylguanine-DNA alkyltransferase. Biochemistry 1999; 38:6801-6.
27. Alvino E, Castiglia D, Caporali S, Pepponi R, Caporaso P, Lacal PM, et al. A single cycle of treatment with temozolomide, alone or combined with O(6)-benzylguanine, induces strong chemoresistance in melanoma cell clones in vitro: role of O(6)-methylguanine-DNA methyltransferase and the mismatch repair system. Int J Oncol 2006; 29:785-97.
28. Christmann M, Pick M, Lage H, Schadendorf D, Kaina B. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 2001; 92:123-9.
29. Naumann SC, Roos WP, Jost E, Belohlavek C, Lennerz V, Schmidt CW, et al. Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT MMR, DSBs and p53. Br J Cancer 2009; 100:322-33.
30. Koch D, Hundsberger T, Boor S, Kaina B. Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma. J Neurooncol 2007; 82:85-9.
31. 6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors. J Clin Oncol 2005; 23:7646-53.
32. Waters TR, Swann PF. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 1997; 36:2501-6.
33. 4-methylthymine with similar efficiency. Biochemistry 1997; 36:11118-24.
34. 6-methylguanine-DNA methyltransferase associated with resistance to alkylating drugs in a mammalian cell line. J Biol Chem 1997; 272:13250-4.
35. 6-methylguanine-DNA methyltransferase gene in cultured human tumor cells. Mutat Res 1992; 273:221-30.
36. 6-benzylguanine. Mol Cancer Ther 2006; 5:732-8.
37. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma. Clin Cancer Res 2005; 11:7861-5.
38. de Boer NK, Derijks LJ, Keizer-Garritsen JJ, Lambooy LH, Ruitenbeek W, Hooymans PM, et al. Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease. J Clin Pharmacol 2007; 47:187-91.
39. Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis. Eur J Gastroenterol Hepatol 2004; 16:1407-13.
40. Karran P, Attard N. Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8:24-36.